Skip to main content
Premium Trial:

Request an Annual Quote

Eurogentec and Exiqon in Licensing Agreement

NEW YORK, March 19 -- Eurogentec of Sart-Tilman, Belgium, today announced a non-exclusive licensing agreement to manufacture and sell modified oligonucleotides produced with Exiqon's locked nucleic acid technology.


LNA is a proprietary nucleic acid analog, which is incorporated in synthetic DNA oligos to enhance sensitivity in genomics products. Eurogentec said in a statement that it plans to use the technology to develop new applications for expression profiling and real-time PCR. The products will be synthesized in Oswell, UK.


Exiqon is based in Copenhagen, Denmark.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.